Skip to main content
SpringerLink
Log in

Influence of CYP2C9 and CYP2D6 Polymorphisms on the Pharmacokinetics of Nateglinide in Genotyped Healthy Volunteers

  • Original Research Article
  • Published:
Clinical Pharmacokinetics Aims and scope Submit manuscript

Abstract

Background: The oral hypoglycaemic drug nateglinide is eliminated from the human body via hepatic biotransformation and renal tubular secretion. According to in vitro data, about 70% of nateglinide intrinsic clearance may be mediated by cytochrome P450 (CYP) 2C9 and a smaller fraction by CYP3A4 and CYP2D6. Objective: To assess the impact of CYP2C9 polymorphisms and of the CYP2D6 poor metaboliser genotype on the pharmacokinetics of nateglinide and its effects on insulin, glucose and glucagon in plasma.

Design and participants: A prospective clinical study in 26 healthy volunteers chosen for their CYP2C9 and CYP2D6 genotype was conducted with individuals carrying wild-type genotype as reference group.

Methods: Serial plasma nateglinide, glucose, insulin and glucagon concentrations were measured over 34 hours after a 180mg dose of nateglinide under challenge with 75g of oral glucose at 0, 4 and 8 hours after nateglinide intake. Kinetics were evaluated by nonparametric methods and by population pharmacokinetic-pharmacodynamic modelling.

Results: Significantly reduced oral nateglinide clearance was found in carriers of CYP2C9*3 alleles, (p < 0.01), whereas carriers of CYP2C9*2 alleles had kinetic parameters similar to those of carriers of the wild-type allele (p = nonsignificant). Median total clearances were 7.9, 8.4, 6.5, 6.9, 5.8 and 4.1 L/h in carriers of the CYP2C9 genotypes *1/*1, *1/*2, *2/*2, *1/*3, *2/*3 and *3/*3. Median clearance in three carriers of two deficient CYP2D6 alleles was 9.4 L/h. These differences in nateglinide kinetics due to CYP2C9 genotypes did not result in statistically significant differences in plasma glucose, insulin and glucagon. Pharmacokinetic-pharmacodynamic modelling revealed a minor effect of CYP2C9 genotype on insulin and glucose, and extrapolations indicated that carriers of the CYP2C9*3/*3 genotype may be at a slightly higher risk of hypoglycaemia compared with carriers of CYP2C9*1, particularly when taking nateglinide doses above 120mg.

Conclusion: The effect of CYP2C9 polymorphisms on nateglinide kinetics may cause a slightly increased risk for hypoglycaemia, which may become relevant in diabetic patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Fig. 1
Fig. 2
Table II
Fig. 3
Table III
Table IV
Fig. 4
Fig. 5

Similar content being viewed by others

Notes

  1. The use of trade names is for product identification purposes only and does not imply endorsement.

References

  1. Shinkai H, Toi K, Kumashiro I, et al. N-acylphenylalanines and related compounds: a new class of oral hypoglycemic agents. J Med Chem 1988; 31(11): 2092–7

    Article  PubMed  CAS  Google Scholar 

  2. Fujitani S, Yada T. A novel D-phenylalanine-derivative hypoglycemic agent A-4166 increases cytosolic free Ca2+ in rat pancreatic beta-cells by stimulating Ca2+ influx. Endocrinology 1994; 134(3): 1395–400

    Article  PubMed  CAS  Google Scholar 

  3. Akiyoshi M, Kakei M, Nakazaki M, et al. A new hypoglycemic agent, A-4166, inhibits ATP-sensitive potassium channels in rat pancreatic beta-cells. Am J Physiol 1995; 268 (2 Pt 1): E185–93

    PubMed  CAS  Google Scholar 

  4. Marre M, Van Gaal L, Usadel KH, et al. Nateglinide improves glycaemic control when added to metformin monotherapy: results of a randomized trial with type 2 diabetes patients. Diabetes Obes Metab 2002; 4(3): 177–86

    Article  PubMed  CAS  Google Scholar 

  5. Kalbag JB, Walter YH, Nedelman JR, et al. Mealtime glucose regulation with nateglinide in healthy volunteers: comparison with repaglinide and placebo. Diabetes Care 2001; 24(1): 73–7

    Article  PubMed  CAS  Google Scholar 

  6. Kikuchi M. Modulation of insulin secretion in non-insulindependent diabetes mellitus by two novel oral hypoglycaemic agents, NN623 and A4166. Diabet Med 1996; 13 (9 Suppl. 6): S151–5

    PubMed  CAS  Google Scholar 

  7. Hanefeld M, Bouter KP, Dickinson S, et al. Rapid and shortacting mealtime insulin secretion with nateglinide controls both prandial and mean glycemia. Diabetes Care 2000; 23(2): 202–7

    Article  PubMed  CAS  Google Scholar 

  8. Weaver ML, Orwig BA, Rodriguez LC, et al. Pharmacokinetics and metabolism of nateglinide in humans. Drug Metab Dispos 2001; 29(4 Pt 1): 415–21

    PubMed  CAS  Google Scholar 

  9. Takesada H, Matsuda K, Ohtake R, et al. Structure determination of metabolites isolated from urine and bile after administration of AY4166, a novel D-phenylalanine-derivative hypoglycemic agent. Bioorg Med Chem 1996; 4(10): 1771–81

    Article  PubMed  CAS  Google Scholar 

  10. Cao G, Song Y. Pharmacokinetics of enantiomers of a new antidiabetic agent (AY4166) in healthy subjects and its metabolism using isolated rats hepatocytes [abstract]. Clin Pharmacol Ther 2002; 71(2): P100

    Google Scholar 

  11. Hatorp V, Walther KH, Christensen MS, et al. Single-dose pharmacokinetics of repaglinide in subjects with chronic liver disease. J Clin Pharmacol 2000; 40(2): 142–52

    Article  PubMed  CAS  Google Scholar 

  12. Kidd RS, Straughn AB, Meyer MC, et al. Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9*3 allele. Pharmacogenetics 1999; 9(1): 71–80

    Article  PubMed  CAS  Google Scholar 

  13. Kirchheiner J, Bauer S, Meineke l, et al. Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and on the insulin and glucose response in healthy volunteers. Pharmacogenetics 2002; 12: 101–9

    Article  PubMed  CAS  Google Scholar 

  14. Kirchheiner J, Brockmöller J, Meineke I, et al. Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers. Clin Pharmacol Ther 2002; 71(4): 286–96

    Article  PubMed  CAS  Google Scholar 

  15. Sullivan-Klose TH, Ghanayem BI, Bell DA, et al. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 1996; 6(4): 341–9

    Article  PubMed  CAS  Google Scholar 

  16. Shon JH, Yoon YR, Kim KA, et al. Effects of CYP2C19 and CYP2C9 genetic polymorphisms on the disposition of and blood glucose lowering response to tolbutamide in humans. Pharmacogenetics 2002; 12(2): 111–9

    Article  PubMed  CAS  Google Scholar 

  17. Baldwin SJ, Clarke SE, Chenery RJ. Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone. Br J Clin Pharmacol 1999; 48(3): 424–32

    Article  PubMed  CAS  Google Scholar 

  18. Ieiri I, Tainaka H, Morita T, et al. Catalytic activity of three variants (Ile, Leu, and Thr) at amino acid residue 359 in human CYP2C9 gene and simultaneous detection using single-strand conformation polymorphism analysis. Ther Drug Monit 2000; 22(3): 237–44

    Article  PubMed  CAS  Google Scholar 

  19. Stubbins MJ, Harries LW, Smith G, et al. Genetic analysis of the human cytochrome P450 CYP2C9 locus. Pharmacogenetics 1996; 6(5): 429–39

    Article  PubMed  CAS  Google Scholar 

  20. Yasar U, Eliasson E, Dahl ML, et al. Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population. Biochem Biophys Res Commun 1999; 254(3): 628–31

    Article  PubMed  CAS  Google Scholar 

  21. Steward DJ, Haining RL, Henne KR, et al. Genetic association between sensitivity to warfarin and expression of CYP2C9*3. Pharmacogenetics 1997; 7(5): 361–7

    Article  PubMed  CAS  Google Scholar 

  22. Furuya H, Fernandez Salguero P, Gregory W, et al. Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy. Pharmacogenetics 1995; 5(6): 389–92

    Article  PubMed  CAS  Google Scholar 

  23. Miners JO, Birkett DJ. Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br J Clin Pharmacol 1998; 45(6): 525–38

    Article  PubMed  CAS  Google Scholar 

  24. Choudhury S, Hirschberg Y, Filipek R, et al. Single-dose pharmacokinetics of nateglinide in subjects with hepatic cirrhosis. J Clin Pharmacol 2000; 40(6): 634–40

    Article  PubMed  CAS  Google Scholar 

  25. Kessler HH, Muhlbauer G, Stelzl E, et al. Fully automated nucleic acid extraction: MagNA Pure LC. Clin Chem 2001; 47(6): 1124–6

    PubMed  CAS  Google Scholar 

  26. Aynacioglu AS, Brockmöller J, Bauer S, et al. Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin. Br J Clin Pharmacol 1999; 48(3): 409–15

    Article  PubMed  CAS  Google Scholar 

  27. Sachse C, Brockmöller J, Bauer S, et al. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 1997; 60(2): 284–95

    PubMed  CAS  Google Scholar 

  28. de Morais SM, Wilkinson GR, Blaisdell J, et al. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 1994; 269(22): 15419–22

    PubMed  Google Scholar 

  29. Bauer S, Störmer E, Kirchheiner J, et al. Rapid and simple method for the analysis of nateglinide in human plasma using HPLC analysis with UV detection. J Pharm Biomed Anal 2003; 31(3): 551–5

    Article  PubMed  CAS  Google Scholar 

  30. Kirchheiner J, Meineke I, Müller G, et al. Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers. Pharmacogenetics 2002; 12(7): 571–80

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

This study was supported by the German Ministry of Education and Research, BMBF grant no. 01 GG 9845/5 and Grant no. 031U209B. The authors have provided no information on conflicts of interest directly relevant to the content of this study.

Author information

Authors and Affiliations

  1. Institute of Clinical Pharmacology, Charité, Humboldt University of Berlin, Schumannstrasse 20/21, Berlin, 10098, Germany

    Julia Kirchheiner, Göran Müller, Steffen Bauer, Christian Meisel, Ivar Roots & Jürgen Brockmöller

  2. Department of Clinical Pharmacology, Georg August University Göttingen, Göttingen, Germany

    Ingolf Meineke & Jürgen Brockmöller

  3. Institute of Experimental Endocrinology, University Medical Center Charité, Berlin, Germany

    Wolfgang Rohde

Authors
  1. Julia Kirchheiner
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ingolf Meineke
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Göran Müller
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Steffen Bauer
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Wolfgang Rohde
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Christian Meisel
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ivar Roots
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Jürgen Brockmöller
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Julia Kirchheiner.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kirchheiner, J., Meineke, I., Müller, G. et al. Influence of CYP2C9 and CYP2D6 Polymorphisms on the Pharmacokinetics of Nateglinide in Genotyped Healthy Volunteers. Clin Pharmacokinet 43, 267–278 (2004). https://doi.org/10.2165/00003088-200443040-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003088-200443040-00005

Keywords

Search

Navigation